Cell and Gene Roundup: CAR T Breaks New Ground - Takeaway - MDSpire
Feature

Cell and Gene Roundup: CAR T Breaks New Ground

A campus-built therapy enters clinical trials as researchers refine gene editing and uncover new ways to control gene expression

  • April 15, 2026

  • 6 min

Share

  • 1

    FDA approval for CAR T therapy at University of Colorado Anschutz.

  • 2

    Targets CD64 protein on AML cells.

  • 3

    Phase 1 trial to assess safety and dosage.

  • 4

    Enrollment of adults with relapsed/refractory AML.

  • 5

    Program emphasizes academic center's capability in cell therapy development.

  • 6

    Potential future pediatric trial planned for

  • 7

    Aims to improve treatment options for aggressive cancers.

Original Source(s)

Cell and Gene Roundup: CAR T Breaks New Ground

  • April 15, 2026

Related Content

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...

Trends and Challenges in Nitrosamine Testing Part Four The Regulatory Landscape

Following part two, which explored the analytical challenges involved in nitrosamine testing, our experts return to offer their top tips for building a method from scratch

  • April 17, 2026

  • 6 min
Is Standard of Care Optimal for the Individual Patient?

I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...